United Therapeutics Corporation

UTHR

NASDAQ. Currency in USD

271.65 -7.31 ( -2.62% )

Real time prices: December 19

Market Cap.
12.38B
Beta (5Y monthly)
0.63
Price/Earnings
19.04
EPS (TTM)
14.70
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
351,985
1y Target Est.
283.42
Day's Range
267.45
-
281.40
52 Week's Range
158.38
-
283.09

Historical Summary

Performance
EPS growth
Share Buybacks

About United Therapeutics Corporation

Sector
Healthcare
Industry
Biotechnology
Website
https://www.unither.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
45.04M
Employees
965
Address
1040 Spring Street, Silver Spring, MD, United States, 20910
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Latest news

The Zacks Analyst Blog Highlights LPL Financial Holdings, Enphase Energy, United Therapeutics, ShockWave Medical and ChampionX
The Zacks Analyst Blog Highlights LPL Financial Holdings, Enphase Energy, United Therapeutics, ShockWave Medical and ChampionX

LPL Financial Holdings, Enphase Energy, United Therapeutics, ShockWave Medical and ChampionX are included in this...
By Zacks Investment Research - 6 weeks ago

UTHR vs. ESALY: Which Stock Is the Better Value Option?
UTHR vs. ESALY: Which Stock Is the Better Value Option?

UTHR vs. ESALY: Which Stock Is the Better Value Option?
By Zacks Investment Research - 6 weeks ago

5 Momentum Stock Bargains Hunters Would Love Chasing
5 Momentum Stock Bargains Hunters Would Love Chasing

Given the prevailing challenges in the market, investors can consider momentum stocks like SNY, GSK,...
By Zacks Investment Research - 6 weeks ago

Top 5 Non-Tech Nasdaq Winners of 2022 With More Upside Left
Top 5 Non-Tech Nasdaq Winners of 2022 With More Upside Left

we have identified five non-technology Nasdaq stocks that have popped in 2022 despite the index's...
By Zacks Investment Research - 6 weeks ago

Zacks.com featured highlights United Therapeutics, StoneCo, Reinsurance Group of America and United Airlines
Zacks.com featured highlights United Therapeutics, StoneCo, Reinsurance Group of America and United Airlines

United Therapeutics, StoneCo, Reinsurance Group of America and United Airlines have been highlighted in this...
By Zacks Investment Research - 7 weeks ago

4 Stocks With Upgraded Broker Ratings for Attractive Returns
4 Stocks With Upgraded Broker Ratings for Attractive Returns

As brokers have a deeper insight into stocks, one must follow rating upgrades before investing....
By Zacks Investment Research - 7 weeks ago

Morgan Stanley Maintains Overweight Rating for United Therapeutics: Here's What You Need To Know
Morgan Stanley Maintains Overweight Rating for United Therapeutics: Here's What You Need To Know

Morgan Stanley has decided to maintain its Overweight rating of United Therapeutics (NASDAQ:UTHR) and raise...
By Benzinga - 7 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022

Upgrades According to Argus Research, the prior rating for United Airlines Holdings Inc (NASDAQ:UAL) was...
By Benzinga - 7 weeks ago